Portland, ME10 Active Studies

Advanced Solid Tumors Clinical Trials in Portland, ME

Find 10 actively recruiting advanced solid tumors clinical trials in Portland, ME. Connect with local research sites and explore new treatment options.

10
Active Trials
9
Sponsors
2,696
Enrolling

Recruiting Advanced Solid Tumors Studies in Portland

RecruitingPortland, MENCT05417594

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

695 participants
AstraZeneca
View Study Details
RecruitingPortland, MENCT05875168

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors....

470 participants
Daiichi Sankyo
View Study Details
RecruitingPortland, MENCT05669430

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care....

365 participants
GV20 Therapeutics
View Study Details
RecruitingPortland, MENCT06873789

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors....

322 participants
Incyte Corporation
View Study Details
RecruitingPortland, MENCT06130553

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...

234 participants
AstraZeneca
View Study Details
RecruitingPortland, MENCT05142592

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 adminis...

196 participants
Nanjing Immunophage Biotech Co., Ltd
View Study Details
RecruitingPortland, MENCT04106492

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors....

145 participants
Shasqi, Inc.
View Study Details
RecruitingPortland, MENCT04892017

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

This is a Phase 1/2, multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or meta...

144 participants
Deciphera Pharmaceuticals, LLC
View Study Details
RecruitingPortland, MENCT06234098

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...

85 participants
Alyssum Therapeutics
View Study Details
RecruitingPortland, MENCT04260256

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT....

40 participants
CellSight Technologies, Inc.
View Study Details

About Advanced Solid Tumors Clinical Trials in Portland

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 10 advanced solid tumors clinical trials recruiting participants in Portland, ME. These studies are seeking a combined 2,696 participants. Research is being sponsored by AstraZeneca, Daiichi Sankyo, GV20 Therapeutics and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Portland — FAQ

Are there advanced solid tumors clinical trials in Portland?

Yes, there are 10 advanced solid tumors clinical trials currently recruiting in Portland, ME. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Portland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you about next steps.

Are clinical trials in Portland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Portland studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 10 active trials in Portland are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated March 2, 2026 from ClinicalTrials.gov